The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Nanodelivery of nucleic acids
Open accessAbstract
There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented opportunity to overcome these drawbacks; owing to their tunability with diverse physico-chemical properties, they can readily be functionalized with any type of biomolecules/moieties for selective targeting. Nucleic acid therapeutics such as antisense DNA, mRNA, small interfering RNA (siRNA) or microRNA (miRNA) have been widely explored to modulate DNA or RNA expression Strikingly, gene therapies combined with nanoscale delivery systems have broadened the therapeutic and biomedical applications of these molecules, such as bioanalysis, gene silencing, protein replacement and vaccines. Here, we overview how to design smart nucleic acid delivery methods, which provide functionality and efficacy in the layout of molecular diagnostics and therapeutic systems. It is crucial to outline some of the general design considerations of nucleic acid delivery nanoparticles, their extraordinary properties and the structure-function relationships of these nanomaterials with biological systems and diseased cells and tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modulation of surface characteris tics may help to improve transduction and reduce the dose required, thereby reducing the risk of GTAU (Mendes et al., 2022; Carvalho et al., 2023).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mendes et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–232 of 232
Nanomedicine-based strategies to target and modulate the tumor microenvironment
Mendes, B. B., Sousa, D. P., Conniot, J., & Conde, J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.001 · Cited by 80
Self-citationComputational design of three-dimensional RNA structure and function
Yesselman, J. D., Eiler, D., Carlson, E. D., Gotrik, M. R., d’Aquino, A. E., Ooms, A. N., Kladwang, W., Carlson, P. D., Shi, X., Costantino, D. A., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0517-8 · Cited by 77
Nanoparticle delivery systems for siRNA-based therapeutics
Li, J., Xue, S., & Mao, Z. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01462c · Cited by 72
Mancheño‐Corvo, P., & Martín‐Duque, P. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0149-y · Cited by 68
Li, S., Meng, F., Wang, Z., Zhong, Y., Zheng, M., Liu, H., & Zhong, Z. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.05.009 · Cited by 61
Poley, M., Mora‐Raimundo, P., Shammai, Y., Kaduri, M., Koren, L., Adir, O., Shklover, J., Shainsky‐Roitman, J., Ramishetti, S., Man, F., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c07237 · Cited by 57
Self-citationSun, Y., Zhao, Y., Zhao, X., Lee, R. J., Teng, L., & Zhou, C. (2017) · Molecules · doi:10.3390/molecules22101724 · Cited by 56
Characterizing the protein corona of sub-10 nm nanoparticles
Glancy, D., Zhang, Y., Wu, J. L. Y., Ouyang, B., Ohta, S., & Chan, W. C. W. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.023 · Cited by 56
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
Tombácz, I., Weissman, D., & Pardi, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 55
Conte, C., Monteiro, P. F., Gurnani, P., Stolnik, S., Ungaro, F., Quaglia, F., Clarke, P. A., Grabowska, A. M., Kavallaris, M., & Alexander, C. (2021) · Nanoscale · doi:10.1039/d1nr02179f · Cited by 52
Supply and delivery of vaccines for global health
Excler, J., Privor-Dumm, L. A., & Kim, J. H. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.03.009 · Cited by 48
Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening
Kohl, Y., Biehl, M., Spring, S., Hesler, M., Ogourtsov, V., Todorović, M., Owen, J., Elje, E., Jakič, K., Moriones, O. H., et al. (2021) · Small · doi:10.1002/smll.202006012 · Cited by 47
Konishcheva, E. V., Zhumaev, U. E., & Meier, W. P. (2017) · Macromolecules · doi:10.1021/acs.macromol.6b02743 · Cited by 43
Setting standards to promote progress in bio–nano science
Lammers, T., & Storm, G. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0497-8 · Cited by 40
Towards vaccine equity: Should big pharma waive intellectual property rights for COVID-19 vaccines?
Okereke, M. (2021) · Public Health in Practice · doi:10.1016/j.puhip.2021.100165 · Cited by 38
Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood
Glass, J. J., Chen, L., Alcântara, S., Crampin, E. J., Thurecht, K. J., Rose, R. D., & Kent, S. J. (2017) · ACS Macro Letters · doi:10.1021/acsmacrolett.7b00229 · Cited by 33
Selot, R., Hareendran, S., & Jayandharan, G. R. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
Corporate Crime in the Pharmaceutical Industry (Routledge Revivals)
Braithwaite, J. B. (2013) · Routledge eBooks · doi:10.4324/9780203597712 · Cited by 29
Inorganic nanovectors for nucleic acid delivery
Pranatharthiharan, S., Patel, M. D., D’souza, A. A., & Devarajan, P. V. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0116-9 · Cited by 26
Nordling‐David, M. M., & Golomb, G. (2013) · Israel Journal of Chemistry · doi:10.1002/ijch.201300055 · Cited by 26
Transmission Electron Microscopy for Chemists
Nakamura, E., Sommerdijk, N. A. J. M., & Zheng, H. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00318 · Cited by 19
Patents and Innovation: Friends or Foes?Preprint
Lévêque, F., & Ménière, Y. (2007) · SSRN Electronic Journal · doi:10.2139/ssrn.958830 · Cited by 19
Preface to the Special Issue on Methods and Protocols in Materials Chemistry
Buriak, J. M. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.6b05235 · Cited by 18
Challenges in the implementation of MIRIBEL criteria on nanobiomed manuscripts
Florindo, H. F., Madi, A., & Satchi‐Fainaro, R. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0498-7 · Cited by 18
Machine learning for next-generation nanotechnology in healthcare
Lorenc, A., Mendes, B. B., Conniot, J., Sousa, D. P., Conde, J., & Rodrigues, T. (2021) · Matter · doi:10.1016/j.matt.2021.09.014 · Cited by 16
Self-citationThe Seasonal Smorgasbord of the Seas
Martín, A. (2012) · Science · doi:10.1126/science.1223881 · Cited by 15
BBB pathophysiology independent delivery of siRNA in traumatic brain injuryPreprint
Li, W., Qiu, J., Li, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.173393 · Cited by 14
Historic Background and Foundation of American Patent Law
Prager, F. D. (1961) · American Journal of Legal History · doi:10.2307/844032 · Cited by 10
Poley, M., Shammai, Y., Kaduri, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.22.216168 · Cited by 9
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · doi:10.1101/2021.08.13.456316 · Cited by 8
(2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0511-1 · Cited by 4
Research works printed but not linked: 1
- Malaviya, M. & Shiroya, M. Systemic gene delivery using lipid envelope systems and its potential in overcoming challenges. Int. J. Pharm. Drug Anal. 9, 46–55 (2021).
Cited by
Sorted by citations
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G. R., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 393
Zhong, R., Talebian, S., Mendes, B. B., Wallace, G. G., Langer, R., Conde, J., & Shi, J. (2023) · Nature Materials · doi:10.1038/s41563-023-01472-w · Cited by 391
Self-citationAGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery
Xu, Y., Ma, S., Cui, H., Chen, J., Xu, S., Gong, F., Golubovic, A., Zhou, M., Wang, K. C., Varley, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50619-z · Cited by 285
Liu, J., Cabral, H., & Mi, P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115239 · Cited by 254
Hosseini-Kharat, M., Bremmell, K. E., & Prestidge, C. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101436 · Cited by 215
Metadata
- Authors
- Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., Shi, J., Schroeder, A., & Conde, J.
- Affiliations
- Ningbo University (CN)
- University of Science and Technology of China (CN)
- Brigham and Women's Hospital (US)
- Technion – Israel Institute of Technology (IL)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Liang, Haojun
- Shi, Jinjun
- Schroeder, Avi
- Conde, João
- ORCID
- Venue
- Nature Reviews Methods Primers
- Published
- 2022-04-14
- Volume
- 2
- Issue
- 1
- ISSN
- 2662-8449 (ISSN-L)
- PMC
- PMC9038125
- OpenAlex
- W4223968391
- Cited by
- 719
- References
- 228
- Citations by year
- 2026: 166 · 2025: 233 · 2024: 196 · 2023: 103 · 2022: 21
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Reviews Methods Primers (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- U.S. Department of Veterans Affairs (I01 BX004426)
- American Lung Association
- Massachusetts General Hospital
- National Natural Science Foundation of China (52003264, 21991132, 52033010, 2020YFA0710700, 52021002)
- National Institutes of Health
- Fundação para a Ciência e a Tecnologia (PTDC/BTM-MAT/4738/2020)
- Fundamental Research Funds for the Central Universities
- National Heart, Lung, and Blood Institute (R01HL159012, R01HL156362, R01HL137229, R01HL158097, R01HL162367)
- National Cancer Institute (R01CA200900)
- H2020 European Research Council (848325)
- DOD Peer Reviewed Cancer Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- nucleic acid delivery, nanodelivery, gene therapy, nanoparticles, siRNA, microRNA, antisense DNA, mRNA therapeutics, targeted delivery, structure-function relationship, molecular diagnosis, gene silencing, vaccines, protein replacement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
